This work is licensed under a Creative Commons Attribution 4.0 International License.
Plitidepsin, Aplidine
General Information
DRACP ID DRACP04351
Peptide Name Plitidepsin, Aplidine
Sequence PxTXXLPX
Sequence Length 8
UniProt ID Not available
PubChem CID Not available
Origin Synthetic
Type Native peptide
Classification
Active ACP
Activity Information
Hemolytic Activity Not available
Normal (non-cancerous) Cytotoxicity Not available
Target Not available
Affinity Not available
Mechanism Not available
Nature Anticancer; Antiviral
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification C3H3O2
C-terminal Modification Free
Other Modification None
Chiral Mix
Physicochemical Information
Formula C20H26N4O2
Absent amino acids ACDEFGHIKMNQRSVWY
Common amino acids X
Mass 80948
Pl 6.11
Basic residues 0
Acidic residues 0
Hydrophobic residues 1
Net charge 0
Boman Index 235
Hydrophobicity -1.25
Aliphatic Index 48.75
Half Life
/
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 1
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 35231500
Title Unraveling the antiviral activity of plitidepsin by subcellular and morphological analysis
Doi Not available
Year 2022
Literature 2
Pubmed ID 33495306
Title Antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A)
Doi Not available
Year 2021
Literature 3
Pubmed ID 22336911
Title Plitidepsin (Aplidin) is a potent inhibitor of diffuse large cell and Burkitt lymphoma and is synergistic with rituximab
Doi Not available
Year 2012
Literature 4
Pubmed ID Not available
Title Antitumoral treatments
Doi Not available
Year 2012
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
External Code
DBAASP ID 18998
This work is licensed under a Creative Commons Attribution 4.0 International License.